Aclaris Therapeutics, Inc. Forecast, price target & analysts
Aclaris Therapeutics, Inc. Target price 2026 - Analyst rating & recommendation
Aclaris Therapeutics, Inc. Classifications & Recommendation
Aclaris Therapeutics, Inc. Price Target
| Target Price | $10.20 |
| Price | $4.41 |
| Potential |
131.29%
register free of charge
|
| Number of Estimates | 14 |
|
14 Analysts have issued a price target Aclaris Therapeutics, Inc. 2027 .
The average Aclaris Therapeutics, Inc. target price is $10.20.
This is
131.29%
register free of charge
$16.80
280.95%
register free of charge
$4.04
8.39%
register free of charge
|
|
| A rating was issued by 18 analysts: 16 Analysts recommend Aclaris Therapeutics, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Aclaris Therapeutics, Inc. stock has an average upside potential 2027 of
131.29%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 7.83 | 6.06 |
| 58.17% | 22.57% | |
| EBITDA Margin | -969.60% | -1,374.89% |
| 252.31% | 41.80% | |
| Net Margin | -829.12% | -1,520.84% |
| 17.52% | 83.43% |
13 Analysts have issued a sales forecast Aclaris Therapeutics, Inc. 2026 . The average Aclaris Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Aclaris Therapeutics, Inc. EBITDA forecast 2026. The average Aclaris Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2025 | $-75.9m | 47.36% |
|---|---|---|
| 2026 |
$-83.4m
9.80%
unlock
|
|
EBITDA Margin
| 2025 | -969.60% | 252.31% |
|---|---|---|
| 2026 |
-1,374.89%
41.80%
unlock
|
|
14 Aclaris Therapeutics, Inc. Analysts have issued a net profit forecast 2026. The average Aclaris Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.53 | -0.66 |
| 69.01% | 24.53% | |
| P/E | negative | |
| EV/Sales | 91.97 |
14 Analysts have issued a Aclaris Therapeutics, Inc. forecast for earnings per share. The average Aclaris Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Aclaris Therapeutics, Inc....
Current Aclaris Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Sep 01 2026 |
| LifeSci Capital |
Locked
➜
Locked
|
Locked | Jun 02 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | May 05 2026 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | May 05 2026 |
| Wedbush |
Locked
➜
Locked
|
Locked | Apr 29 2026 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Apr 16 2026 |
| Wedbush |
Locked
➜
Locked
|
Locked | Mar 31 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Sep 01 2026 |
|
Locked
LifeSci Capital:
Locked
➜
Locked
|
Jun 02 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
May 05 2026 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
May 05 2026 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Apr 29 2026 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Apr 16 2026 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Mar 31 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
